Shout out to @OSUCCC_James & for enrolling its first patient in PrE0510, our phase 2 #ClinicalTrial exploring the optimal dose of ivonescimab with carboplatin and etoposide in extensive-stage #SmallCellLungCancer (#SCLC). Learn more: bit.ly/PrE0510
Innovative cancer research studies developed through industry partnerships and networks. Supporting ECOG-ACRIN's efforts to advance cancer care